About

History

History

2024

02 Fundraising from SI partner (BNC Korea)
Starting Joint R&D program on anti-obesity
asset with BNC Korea
08 Government R&D grant from Seoul R&D Fund (Obesity)
Patent Registration of Platform Technology in Korea

2023

02 Patent for PAT101 registered in Korea
04 Government R&D grant of
Korea Drug Development Fund (Gout)
06 Innovation Startup Package Grant
07 PCT patent application for
Albubody Platform Technology
11 Patent for PAT101 registered in the US

2022

02 Licensed-in manufacturing
bacterial strains ( Harvard University )
03 Designated as Gwangju Global IP Star Company
04 Executing an Industry-Academia-Research Collaboration
R&D Project by the Ministry of SMEs
and Startups (Metabolic Anticancer Drugs)
04 Executing an INNOPOLIS(Korea innovation foundation)
R&D Project (anti-obesity drugs)
09 Contract with IPO coordinators
(Samsung Securities/Hana Securities)

2021

01 Patent application of Platform Technology
for therapeutic proteins
03 Contract with Quratis for PAT101 manufacturing
04 Win the grand prize in IR pitch contest
from Korea Securities Depository
07 Contract with Charles River
for PAT101 non-clinical studies
10 Series A-1 capital increase
11 Award from Korean government
(excellent IP-R&D institute)
11 Supply agreement for rHSA with Albumedix

2020

06 PCT patent application
for new gout treatment candidate
08 Series A capital increase
09 Seoul R&D center opened
12 Award from Mayor of Gwangju city

2019

05 Government R&D grant of TIPS program
06 2nd Seed Fundraising from MAGNA – INVESTMENT
10 Patent application for Alburicase

2018

05 Certificate of Frontier venture company
(Korea Technology Guarantee Fund)
11 Governmet R&D grant from Ministry of SMEs and Startups

2017

09 Founded (GIST business Incubator)
11 Licensed-in therapeutic candidate drug from GIST
12 Seed Fundraising (Mirae Holdings)

KOR